Detected ·
Crystalys Therapeutics
$130M—
Crystalys Therapeutics closed an oversubscribed $130M Series B financing led by Frazier Life Sciences, with participation from Wellington Management, HBM Healthcare Investments, and existing investors including AN Venture Partners. Funds will advance dotinurad's late-stage global Phase 3 clinical development for gout in the US and Europe.
- Website
- crystalystx.com
- Amount
- $130 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-11 00:03:26 UTC
- Signal ID
- e376c0ae-f082-4d17-80a5-34430596cd82
As the API returns it
{
"id": "e376c0ae-f082-4d17-80a5-34430596cd82",
"created_at": "2026-08-11T00:03:26.641048Z",
"company_name": "Crystalys Therapeutics",
"company_website_url": "crystalystx.com",
"company_linkedin_url": "https://www.linkedin.com/company/crystalys-therapeutics",
"event_type": "funding",
"funding_amount": 130000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Crystalys Therapeutics closed an oversubscribed $130M Series B financing led by Frazier Life Sciences, with participation from Wellington Management, HBM Healthcare Investments, and existing investors including AN Venture Partners. Funds will advance dotinurad's late-stage global Phase 3 clinical development for gout in the US and Europe.*"
}